Introduction
Unstable angina (UA) is still one of the major cardiovascular causes of hospital admission. Some patients with UA develop elevations in biochemical markers of myocardial injury, characterizing myocardial infarction (MI) without ST-segment elevation (NSTEMI). Those two entities (UA and NSTEMI) make up the non-ST-elevation acute coronary syndromes (NSTE-ACS), the object of this guideline.
Clinical history, physical examination and risk scores
Clinical history and physical examination play fundamental roles in the risk stratification of patients with NSTE-ACS. The classification proposed by Braunwald, as well as its update, including troponin measurement, provide a rapid assessment of the patients' risk for major ischemic outcomes 1 .
Mathematical tools, such as TIMI and GRACE scores, can provide prognostic information and guide risk stratification, as well as antithrombotic therapy 2, 3 . (Figure 1 and Table 1) The occurrence of major bleeding in patients with NSTE-ACS relates directly to adverse events (including mortality), and the use of bleeding scores (CRUSADE and ACUITY/HORIZONS), which estimate the risk of hemorrhagic complications, guide the therapy to minimize those outcomes 4, 5 . (Tables 2 and 3) Electrocardiogram Despite its low sensitivity to discriminate a subendocardial MI from a transmural MI (by use of Q wave), the electrocardiogram (ECG) is fundamental to the management of patients with NSTE-ACS. Transient changes in the ST segment (depression or elevation), as well as T-wave inversions, are important prognostic markers of death or infarction. However, a normal ECG does not exclude the diagnosis of NSTE-ACS. It has prognostic importance, and the GUSTO II study has related initial ECG to early mortality as follows: left bundle branch block, left ventricular hypertrophy or pacemaker rhythm related to a mortality of 11.6%; ST-segment depression, mortality of 8%; ST-segment elevation, mortality of 7.4%; and T-wave inversion or normal ECG, mortality of 1.2% 6 .
Biochemical markers of myocardial necrosis
The modern biochemical markers (troponin and CKMB mass) are important tools for the diagnosis and prognosis of patients with NSTE-ACS. They should be interpreted in association with clinical and ECG findings, considering that several non-coronary conditions can determine their elevation 7 .
After percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), elevations in the levels of necrosis markers 5 and 10 times their reference values (post-PCI and post-CABG, respectively) indicate MI when interpreted in association with symptoms, ECG changes and/or imaging tests 8 .
Myoglobin and high-sensitivity troponins, due to their high negative predictive value 6 hours after symptom onset, can be considered in protocols of early discharge from the emergency unit 9 .
Exercise testing
Patients with NSTE-ACS should undergo exercise testing (ET) with the following purposes: to identify occasional myocardial ischemia, to estimate prognosis and to guide proper clinical decisions, such as treatment strategies. It is recommended to patients at low risk as a first choice test, because it is a low-cost, low-risk, widely available procedure. A negative ET correctly indicated to a patient with good functional capacity allows immediate hospital discharge, because the test has a high negative predictive value 10 . Echocardiography Echocardiography is extremely useful in patients with NSTE-ACS 11 . The detection of changes in segmentary contraction strongly indicates coronary artery disease (CAD), because it can represent infarction, ischemia or both. In addition, it plays an important role in the differential diagnosis of chest pain (aortic dissection, aortic stenosis, pulmonary embolism, hypertrophic cardiomyopathy and pericardial disease) and in prognostic assessment via left ventricular ejection fraction (LVEF).
Nuclear cardiology
For patients with NSTE-ACS, the prognostic role of the information provided by nuclear imaging (myocardial In the emergency unit setting or in the presence of acute pain, the radiotracer should be injected only at rest, while the patient is still symptomatic (exceptionally after the end of the symptoms), and the images should be obtained in up to 6 hours. If considered to be of low risk, it indicates a very low likelihood of subsequent cardiac events 12, 13 .
Risk strati cation

Coronary computed tomography angiography
Coronary computed tomography angiography is an important tool to assess patients with acute chest pain, especially those at low and intermediate risk. It is safe for the diagnosis of NSTE-ACS and can reduce the length of hospital stay, and, thus, total cost.
Criteria for hospital discharge of low-risk patients in the first 12 hours of stratification
The criteria are lack of pain, clinical stability, normal ECG or ECG with no acute change, normal levels of myocardial necrosis biochemical markers, and negative provocative test of coronary spasm, when performed.
Part II -Management of intermediate-and high-risk patients
Admission to and discharge from the coronary care unit
All intermediate-and high-risk patients with NSTE-ACS should be admitted to the coronary care unit (CCU) whenever possible. Those undergoing PCI should return to the CCU after the procedure; in the absence of complication, they should be discharged from the CCU on the following day. When CABG is the treatment option, the patient should remain at the CCU up to surgery time. Those undergoing exclusive clinical pharmacological treatment should be discharged from the CCU on the day following that decision, provided they are stable and require no intravenous drug.
Oxygen therapy
Limited and old evidence suggests that oxygen administration can limit the extension of acute ischemic injury 14 . Usually oxygen supplementation is maintained for up to 4 hours after pain subsides. If hypoxia persists, oxygen supplementation will be kept according to clinical need. Unnecessary oxygen administration for prolonged time can cause systemic vasoconstriction and even be harmful.
Analgesia and sedation
The chest pain and anxiety of NSTE-ACS usually lead to hyperactivity of the sympathetic nervous system. In addition to increasing myocardial oxygen consumption, that hyperadrenergic state predisposes to atrial and ventricular tachyarrhythmias. Thus, strong analgesic drugs are recommended to patients with severe ischemic pain, who are refractory to antianginal therapy 15 . When pain is not relieved with sublingual nitrate, or when pain recurs despite adequate anti-ischemic therapy, morphine sulfate is the analgesic of choice, and should be intravenously administered, diluted at the dose of 2 to 4 mg every 5 minutes up to 25 mg, with blood pressure monitoring.
Nitrates
The use of nitrates is based on their mechanism of action and clinical experience over several years of use. No controlled clinical trial has tested the effects of nitrates on clinical outcomes and mortality in UA, although their use is universally accepted 16, 17 . The treatment is initiated at the emergency room, with sublingual administration of nitrate. If no rapid relieve of the pain occurs, those patients can benefit from the intravenous administration of nitroglycerin. Nitrates are contraindicated in the presence of important arterial hypotension (systolic blood pressure < 100 mmHg) or previous use of sildenafil in the past 24 hours. The intravenous treatment should be maintained for 24-48 hours after the last episode of anginal pain, and suspended gradually.
Beta-adrenergic blockers
By decreasing heart rate, blood pressure and myocardial contractility, betablockers reduce myocardial oxygen uptake. Despite the lack of large-scale randomized studies assessing their action on major clinical outcomes, such as mortality, these drugs, along with nitrates, are considered first-choice agents in the treatment of NSTE-ACS 18 .
They should be initiated orally for stable patients with no contraindication, at low doses, which should be gradually increased to maintain heart rate around 60 bpm. If ischemic pain and/or tachycardia (not compensatory for heart failure) persists, the intravenous formulation can be used. 
Calcium channel blockers
The beneficial effects of calcium channel blockers on NSTE-ACS derive from the combination of their actions, reducing myocardial oxygen uptake, afterload, contractility and heart rate, in addition to increasing myocardial oxygen supply via coronary dilatation. Calcium channel blockers can be used to control refractory ischemic symptoms in patients already on adequate doses of nitrates and betablockers, or in those who do not tolerate those drugs (mainly those with contraindication), or those with variant angina (Prinzmetal syndrome). In patients with impaired left ventricular function and/or atrioventricular conduction changes, calcium channel blockers should be avoided 19 .
Inhibitors of the renin-angiotensin-aldosterone system
There is no conclusive evidence about the benefits of the early use of renin-angiotensin-aldosterone inhibitors to patients with NSTE-ACS, although some studies have suggested they can be useful in the chronic phase 20 .
Antiplatelet agents Acetylsalicylic acid
Coronary thrombosis plays an important role in NSTE-ACS triggering and progression, antithrombotic therapy being thus essential for patients with those syndromes. Acetylsalicylic acid (ASA) is the best antiplatelet agent, and should always be prescribed, except for the rare cases of previously known severe allergic reaction and the existence of active digestive bleeding 21 .
Thienopyridine derivatives
Thienopyridine derivatives are antagonists of the platelet activation mediated by the platelet adenosine diphosphate (ADP) receptor (P2Y 12 ).
Clopidogrel in addition to AAS to treat intermediate-to high-risk NSTE-ACS was related to a 20% reduction in the risk of cardiovascular death, MI or stroke 22 . When the dose was doubled (600 mg loading dose, followed by 150 mg daily for 6 days), a 14% reduction in the risk of cardiovascular death, MI or stroke was observed in patients undergoing PCI (NNT, 167). However, a 41% increase in the occurrence of severe bleeding was observed (NNH, 200) 23 . Because the NNT to avoid an ischemic event is similar to the number of patients treated who will have a severe hemorrhagic event, careful and individualized assessment is recommended for each case.
The platelet aggregation inhibition of patients on clopidogrel has shown a wide intra-and interindividual variation. "Poor response" and "resistance" to clopidogrel are terms used to characterize patients who do not reach the expected platelet inhibition level. Consistent data have associated poor response to clopidogrel to the greater incidence of thrombotic events, mainly in patients undergoing PCI with stent implantation. Several strategies have been tested to decrease resistance to clopidogrel, but no significant positive impact has been observed on the reduction of clinical events 24 .
The association of clopidogrel with proton pump inhibitors (PPI), mainly omeprazole, has been related to a higher incidence of resistance to clopidogrel. Despite conflicting data, the routine use of PPI should be avoided and histamine H 2 receptor antagonists should be preferred 25 .
Prasugrel is a third-generation thienopyridine derivative, which provides greater and more consistent platelet inhibition levels. Compared to clopidogrel when used for patients with high-risk acute coronary syndrome (ACS) undergoing PCI, prasugrel was associated with a 19% reduction in the occurrence of cardiovascular death, MI or stroke. However, the use of prasugrel was associated with a 32% increase in the occurrence of severe bleeding. For patients undergoing CABG, clopidogrel should be suspended at least 5 days before the procedure, while prasugrel should be suspended 7 days before.
Cyclopentyl-triazolo-pyrimidine
Ticagrelor is a cyclopentyl-triazolo-pyrimidine (CPTP) with a 12-hour half-life, which, unlike thienopyridine derivatives, exerts a reversible block of P2Y 12 receptors and whose action does not depend on liver metabolism. With such characteristics, ticagrelor has a more intense, rapid and consistent antiplatelet effect as compared to clopidogrel. In patients with intermediate-and high-risk ACS, as compared to clopidogrel, ticagrelor was associated with a significant 16% reduction in the occurrence of combined outcome of vascular death, MI or stroke. In addition, a 21% reduction in vascular deaths and a 22% reduction in all-cause mortality occurred. No significant increase in major hemorrhagic events, fatal bleeding or need for transfusion has been reported with ticagrelor; however, an increase in major bleeding not related to CABG has been reported. In addition, the use of ticagrelor has been associated with a higher incidence of dyspnea and transient ventricular pauses, as well as with an increase in creatinine and uric acid levels. In patients undergoing CABG, ticagrelor should be suspended 5 days before the procedure 27 .
Glycoprotein IIb/IIIa receptor inhibitors
That class of drugs blocks the common final pathway of platelet aggregation, regardless of the initial stimulus. By inhibiting glycoprotein (GP) IIb/IIIa receptors on platelet surface, those inhibitors prevent fibrinogen from binding to activated receptors, blocking platelet aggregation and platelet thrombus formation.
In the context of patients with NSTE-ACS undergoing an essentially "conservative" strategy, GP IIb/IIIa inhibitors have their use supported by studies on heparinization plus ASA 28, 29 . Despite their extremely heterogeneous results, usually suggesting benefits deriving from the use of small-molecule GP IIb/IIIa inhibitors, but not from abxicimab, a meta-analysis 30 has shown an only 9% reduction in the relative risk of death or infarction at 30 days of follow-up (p = 0.015), the benefit being restricted to higher-risk patients (high troponin and/or ST-segment depression and/or undergoing PCI).
Patients on oral dual antiplatelet therapy conducted via an early invasive strategy, GP IIb/IIIa inhibitors can be initiated in the catheterization laboratory, in the presence of high complexity PCI, high thrombotic load, no-reflow phenomenon or multiple instability sites of atherosclerotic plaques. GP IIb/IIIa inhibitors should always be used in an individualized and non-routine way.
Antithrombin agents
Antithrombin therapy should be administered to all moderate and high-risk patients with NSTE-ACS, except when contraindicated. Low-molecular-weight heparins (LMWH) are usually as effective as unfractionated heparin (UNH); however, enoxaparin appears to be superior to UNH 31, 32 . Patients receiving enoxaparin to treat NSTE-ACS and referred for PCI within 8 hours from the last subcutaneous dose require no additional anticoagulation. Those undergoing PCI between 8 and 12 hours should receive an additional intravenous dose of 0.3 mg/kg right before the procedure. The initially used heparin should be maintained during the entire heparinization period, avoiding the concomitant or alternate use of LMWH and UFH. Fondaparinux has demonstrated equivalence with enoxaparin to reduce ischemic events, being associated, however, with a significant reduction in severe bleeding 33 .
Diagnosis and risk stratification with complementary tests
Risk stratification should be a continuous process, from initial clinical assessment, passing by subsidiary tests already discussed in this guideline, and culminating in the complementary tests described below.
Currently there is consistent evidence on the benefit of early "interventional" or "invasive" strategy for NSTE-ACS, aimed at performing coronary angiography usually within 24 hours from admission 34 . It is worth noting that the benefit observed with the "interventional" strategy tends to be greater in the long run than in the initial phase, in which, paradoxically, the risk of using that strategy can be higher 35 . In addition, the higher the risk for ischemic events, the more benefit there is. Furthermore, the appropriate antithrombotic regimen with antiplatelet and antithrombin agents is fundamental for the success of that approach.
Hemodynamic and cineangiocardiographic assessment
It essentially provides direct visualization of the coronary lumen, with assessment of the severity of obstructions, and analysis of the systolic and diastolic ventricular, global and regional functions. In addition, it can assess the functional meaning of anatomically detected lesions, by direct measurement of the coronary fractional flow reserve (FFR). However, it is worth noting that, in the NSTE-ACS context, that complementary test has limited applicability, because of the intrinsic mutability of the obstructions (often ulcerated, complex atherosclerotic plaques with high thrombotic load), and has not been duly validated in proper studies.
Exercise testing
Exercise testing can be the initial risk stratification approach for patients with NSTE-ACS when other non-invasive methods are unavailable and there is no indication for invasive strategy. In addition to diagnostic support, it has a well-known prognostic value. Positive tests are associated with a higher incidence of coronary events within 1 year as compared to negative tests. It is an inexpensive, safe procedure of easy application. Its negative predictive value is very high, 98% to 100%, although its positive predictive value is modest, around 50%. The ET, aimed at estimating prognosis and supporting clinical decision, is mainly indicated for intermediate-risk patients who can perform it 24 to 48 hours after complete clinical stabilization (hemodynamic stability, absence of active clinical or electrocardiographic ischemia, of new Q waves, of clinical signs of heart failure and normal markers of myocardial necrosis), as long as there is physical capacity. The ET should be carried out on a treadmill or cycle ergometer at a hospital, and always be symptom-limited 36 .
Echocardiographic assessments
Stress echocardiography
Stress echocardiography allows the assessment of transient regional abnormalities of contractility, indicative of induced ischemia. Pharmacological stress with dobutamine is safe and effective in that context, and provides prognostic information. However, the same restrictions and contraindications reported for ET apply for stress echocardiography. The following responses indicate higher risk: incapacity to increase EF or an EF reduction > 5% on exertion and regional contractility abnormality during stress. A segmental contractility improvement in dyssynergic areas with initial dobutamine doses (5 to 10 mg/kg/min) identify myocardial viability in those regions "stunned" by previous ischemia.
Studies with myocardial perfusion assessment
The development of contrast media containing smaller microbubbles of higher stability, in association with technological advances, such as intermittent harmonic imaging and low-mechanical index imaging, has allowed the echocardiographic study of myocardial perfusion. The use of contrast media during dobutamine stress echocardiography with real-time imaging analysis provides a simultaneous assessment of myocardial perfusion and of segmental motility changes.
Nuclear medicine methods
Myocardial perfusion imaging
Myocardial perfusion imaging (MPI) and radionuclide ventriculography play a significant role in the diagnosis and prognosis of ACS. Myocardial perfusion imaging is mainly indicated for patients who cannot undergo ET and those whose adequate interpretation of exercise ECG is difficult. Patients diagnosed with NSTE-ACS and having a normal MPI during stress belong to a subgroup with reduced risk of severe events, around 1% in one year. On the other hand, the detection of reversible defects expresses an unfavorable prognosis, with an event rate of 20% in the same follow-up period.
Radionuclide angiocardiography
Radionuclide angiocardiography is obtained by synchronizing the computed tomography scan with ECG (gated SPECT). It allows assessing regional systolic function and estimating ventricular EF, adding diagnostic and prognostic information.
Cardiovascular magnetic resonance
Cardiovascular magnetic resonance (CMR) can provide accurate information on heart morphology, volume quantification, global and regional ventricular mass and function. It allows assessing myocardial ischemia, by analyzing segmental contractility under dobutamine stress and without contrast or via myocardial perfusion under stress with vasodilators, such as dipyridamole or adenosine, and using gadolinium. In addition, it allows the assessment of myocardial fibrosis/necrosis by use of myocardial delayed enhancement. The delayed enhancement technique allows the detection of hyposignal areas (dark) amidst the hypersignal area (infarction), which relates to microvascular obstruction areas (no-reflow phenomenon), adding prognostic information for that population. In addition to those uses, CMR is extremely useful to differentiate ischemic from non-ischemic cardiomyopathies, being used to diagnose myocarditis and Takotsubo cardiomyopathy. Moreover, in the presence of elevation of myocardial necrosis markers and "normal" catheterization, CMR can confirm infarction, which could be related to spasm or thrombophilic syndromes 37 .
Myocardial revascularization
The revascularization strategy (surgery or angioplasty) follows recommendations similar to those for patients with stable CAD. The major difference in the approach of patients with UA or NSTEMI is the greater benefit of early revascularization in those at higher risk for ischemic outcomes.
Patients with NSTE-ACS, especially those classified in the second tertile of the SYNTAX Score, should be assessed by the "Heart Team", and the decision about the type of revascularization, or even the isolated clinical treatment, should also consider circumstantial factors related to the experience of each center.
Myocardial revascularization surgery
The likelihood of complete revascularization is greater with CABG than with angioplasty. The benefit of CABG is greater in the subgroups of patients with diabetes or ventricular dysfunction.
The recently developed SYNTAX Score is a tool to support the revascularization strategy choice, because patients with a SYNTAX Score > 22 have better long-term results when submitted to CABG rather than to angioplasty 38 .
Percutaneous coronary intervention
In past decades, PCI has progressed, with greater experience of interventional cardiologists, better quality of the devices used (catheters, stents, balloons) and more effective and safe adjuvant drugs (antiplatelet and anticoagulant drugs). Such advances have allowed PCI indications to continuously and intensely increase in number, therefore promoting its use in more complex situations (left coronary artery lesions, multivessel disease and left ventricular dysfunction).
The major recommendations and respective levels of evidence in risk stratification and management in the first 12 hours from hospital arrival are shown in tables 4 to 9. All patients with NSTE-ACS or suspected of having NSTE-ACS should undergo ECG. Ideally, ECG should be performed within 10 minutes of hospital arrival (level of evidence: B). ECG should be repeated in non-diagnostic cases at least once within 6 hours
Necrosis biomarkers
I (B)
All patients suspected of having NSTE-ACS should have biomarkers of myocardial necrosis measured. The biomarkers should be measured on admission and repeated at least once 6-9 hours after (preferentially 9-12 hours after symptom onset) if the first measurement is normal or mildly elevated
The CK-MB activity isolated or associated with total CK can be used if CK-MB mass or troponin are not available
IIb (B)
Myoglobin and high-sensitive troponin can be considered in association with a later marker (CK-MB or troponin) for patients who arrive early at the emergency unit (less than 6 hours from symptom onset)
I (A) CK-MB mass and troponins are biomarkers of choice III (B)
Use of LDH, aspartate aminotransferase (GOT) or BNP/pro-BNP to detect myocardial necrosis in patients suspected of having NSTE-ACS
Exercise test
I (B)
Low-risk patients (clinic and ECG) with normal biomarkers should be referred for ET after 9 hours, ideally up to 12 hours, on an outpatient basis I (B) When ET cannot be performed or when ECG cannot be interpreted, the patient can be stratified by using provocative test for ischemia with imaging
Treadmill or cycle ergometer protocols should be adapted to the clinical and biomechanical conditions of each patient
Echocardiography
I (C)
Transthoracic echocardiography should be performed for the differential diagnosis with other diseases, when clinical suspicion of aorta diseases, pericardial diseases, pulmonary embolism and heart valve diseases exists
IIa (B)
In the presence of thoracic pain, patients can be assessed by using rest echocardiography to determine if the pain origin is ischemic or not I (C) In NSTE-ACS complications, such as ventricular septal defect and mitral regurgitation IIa (B) Patients with uncomplicated infarction of the anterior wall to determine the exact size of the ischemic injury
Stress echocardiography is an alternative for patients unable to undergo ET
Myocardial perfusion imaging
I (C) Stress/rest myocardial perfusion imaging is an alternative for patients unable to undergo ET IIa (A)
In the presence of thoracic pain, patients can be assessed by using rest myocardial perfusion imaging to determine if the pain origin is ischemic or not
Coronary computed tomography angiography
I (A)
To assess patients with acute chest pain at low to intermediate risk, with non-diagnostic ECG and negative markers of myocardial necrosis
NSTE-ACS: Non-ST-elevation acute coronary syndromes; ECG: Electrocardiogram; ET: Exercise test. Non-ST-Elevation myocardial infarction
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I (C)
Detailed instructions should be provided to patients with NSTE-ACS, including education on medications, diet and physical exertion, return to work and referral to a cardiac rehabilitation unit/secondary prevention program. Low-risk clinically treated and revascularized patients should have their first follow-up consultation in 2 to 6 weeks, and those at higher risk, within 14 days
Smoking cessation
I (B)
Smoking cessation and no exposure to a smoking environment, at both work and home, are recommended. Long-term follow-up, referral to specific programs or drug therapy, such as nicotine replacement, are useful when associated with classical non-pharmacological strategies
Lipid approach
I (C)
The lipid therapeutic approach should include assessing the fasting lipid profile of all patients within the first 24 hours from hospital admission I (A) For patients with NSTE-ACS and LDL-C ≥ 100 mg/dL, statins should be used unless contraindicated, aiming at reaching the LDL-C < 70 mg/dL goal NSTE-ACS: Non-ST-elevation acute coronary syndromes.
